Evidence map›Paper›PMID 37910381›Full record

ArticleInternational urology and nephrology2024

Comparison of the effect of hyperbaric oxygen therapy and tadalafil daily use on erectile function: a prospective, double controlled study.

Anıl Eker, Serdar Celik, Elif Ebru Ozer, Ismail Basmacı, Ertuğrul Sefik, Ibrahim Halil Bozkurt, Bulent Gunlusoy, Tansu Degirmenci

Abstract read
PubMed Publisher
In one paragraph

Article in International urology and nephrology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 3 citations in OpenAlex.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Anıl EkerDepartment of Urology, Health Sciences University, İzmir Bozyaka Training and Research Hospital, Izmir, Turkey. anileker993@gmail.com.ORCID http://orcid.org/0000-0003-1603-3336
Serdar CelikDepartment of Urology, Health Sciences University, İzmir Bozyaka Training and Research Hospital, Izmir, Turkey.
Elif Ebru OzerDepartment of Hyperbaric Medicine, Health Sciences University, İzmir Bozyaka Training and Research Hospital, Izmir, Turkey.
Ismail BasmacıDepartment of Urology, Health Sciences University, İzmir Bozyaka Training and Research Hospital, Izmir, Turkey.
Ertuğrul SefikDepartment of Urology, Health Sciences University, İzmir Bozyaka Training and Research Hospital, Izmir, Turkey.
Ibrahim Halil BozkurtDepartment of Urology, Health Sciences University, İzmir Bozyaka Training and Research Hospital, Izmir, Turkey.
Bulent GunlusoyDepartment of Urology, Health Sciences University, İzmir Bozyaka Training and Research Hospital, Izmir, Turkey.
Tansu DegirmenciDepartment of Urology, Health Sciences University, İzmir Bozyaka Training and Research Hospital, Izmir, Turkey.
Izmir University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeErectile dysfunction (ED) is a worldwide health problem. Oral phosphodiesterase type 5 inhibitors (PDE5I) are used in its first-line treatment. This study aimed to compare the effects of hyperbaric oxygen (HBO) treatment with PDE5I treatment and determine the patient-dependent factors affecting the efficacy of the HBO treatment and duration of action of HBO treatment.

methodsAdult male patients who presented to the HBO unit for HBO treatment with non-urological indications and had ED based on the International Index for Erectile Function (IIEF-5) constituted the target population of this study. Participants were given HBO treatment (Group 1), no treatment (Group 2), or daily oral tadalafil 5 mg treatment (Group 3). The treatment duration was 1 month. Patients were assessed by IIEF-5 both initially and after the completion of 1 month.

resultsThere were significant increases in the mean IIEF-5 scores of the patients in Group 1 and Group 3 (p < 0.001, p < 0.001). However, there was no significant improvement in Group 2 (p = 0.496). Also, the post-treatment IIEF-5 scores of Group 1 and Group 3 were significantly higher than Group 2 (p < 0.001). There was no significant difference between the IIEF-5 scores and ∆IIEF-5 values of Group 1 and Group 3 (p = 0.166, p = 0.093). Evaluation regarding comorbidities revealed that patients with the peripheral vascular disease did not improve with HBO treatment (p = 0.285).

conclusionHBO can improve erectile functions, and it can be a reasonable alternative for patients who cannot use PDE5Is due to comorbidities or treatment side effects.

Indexed as

Erectile DysfunctionHyperbaric OxygenationAdultCarbolinesDouble-Blind MethodHumansMalePhosphodiesterase 5 InhibitorsProspective StudiesTadalafilTreatment OutcomeCarbolinesPhosphodiesterase 5 InhibitorsTadalafilErectile dysfunctionHyperbaric oxygen treatmentPhosphodiesterase type 5 inhibitorTadalafil

Identifiers

PMID37910381
OpenAlexW4388130652

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.